Literature DB >> 4038381

Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.

E Boven, W J van der Vijgh, M M Nauta, H M Schlüper, H M Pinedo.   

Abstract

The antitumor activity of four new platinum analogues was compared at equitoxic doses to that of cisplatin in B10 LP/cpb nude mice bearing xenografts of human ovarian carcinomas. The two tumor lines used, MRI-H-207 and Pe, differ in histology, tumor doubling time, and sensitivity to cisplatin. Complete remission of MRI-H-207 was observed with cisplatin, carboplatin, iproplatin, and JM-40, while spiroplatin only gave growth delay. Cisplatin and carboplatin caused some growth delay of Pe, while JM-40, spiroplatin, and iproplatin failed to affect tumor growth. Platinum tissue distribution was also measured for each compound in groups of five to seven tumor-bearing mice. Platinum concentrations in the two tumors at 24 hr were similar for cisplatin and carboplatin, but differed for iproplatin, spiroplatin, and JM-40. Organ distribution was similar for each analogue, and concentrations were significantly higher in kidneys than in liver, except for iproplatin with comparable concentrations in these organs. Our findings show a good correlation between analogue activity in ovarian cancer in the clinic and that in MRI-H-207. Platinum concentrations in tumor tissue did not predict antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038381

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.

Authors:  E Boven; M M Nauta; H M Schlüper; C A Erkelens; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors.

Authors:  R Riccardi; A Riccardi; C Di Rocco; G Carelli; R L Tartaglia; A Lasorella; T Servidei; R Mastrangelo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

Authors:  L R Kelland; M Jones; G Abel; M Valenti; J Gwynne; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.

Authors:  L T Vlasveld; J H Beynen; W Boogerd; W W Ten Bokkel Huinink; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser.

Authors:  G Milano; V Troger; A Courdi; X Fontana; P Chauvel; J L Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay.

Authors:  M G Daidone; R Silvestrini; N Zaffaroni; E Grignolio; F Landoni
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

7.  Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay.

Authors:  W Schroyens; P Dodion; M Rozencweig
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

8.  Development of new anti-cancer drugs.

Authors:  H M Pinedo
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

Review 9.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

10.  Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA).

Authors:  M Poisson; Y Péréon; J Chiras; J Y Delattre
Journal:  J Neurooncol       Date:  1991-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.